ConductScience.org, home

Comparison · NCT00605865-6ce6c171

15 Years and Higher vs Under 15 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 15 Years and Higher vs Under 15 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not. Trial comparisons, record NCT00605865-6ce6c171. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00605865-6ce6c171

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1210.1080.136wilson
Risk in group 20.50.150.85wilson
Risk difference, group 1 minus group 2-0.379-0.729-0.0285newcombe hybrid score
Risk ratio, group 1 over group 20.2420.09040.65log
Odds ratio, group 1 over group 20.1380.01930.984log
Number needed to treat, for one fewer participant with the outcome on 15 Years and Higher than on Under 15 Years2.641.3735.1from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 115 Years and HigherParticipants 15 years and higher of age who took Sertraline according to Japanese Package Insert2612,153OG000
Group 2Under 15 YearsParticipants under 15 years of age who took Sertraline according to Japanese Package Insert24OG001

Outcome

Type
SECONDARY
Title
Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not
Description
Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether 15 years and higher of age or not is significant risk factor
Time frame
Baseline up to 16 weeks
Population
The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.

Source ClinicalTrials.gov

Trial

Title
Drug Use Investigation of Jzoloft.
NCT number
NCT00605865
Phases
Conditions
Panic Disorder, Depression
Interventions
Sertraline hydrochloride
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Results first posted
2012-10-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00605865-6ce6c171